JPWO2019236631A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019236631A5
JPWO2019236631A5 JP2020567845A JP2020567845A JPWO2019236631A5 JP WO2019236631 A5 JPWO2019236631 A5 JP WO2019236631A5 JP 2020567845 A JP2020567845 A JP 2020567845A JP 2020567845 A JP2020567845 A JP 2020567845A JP WO2019236631 A5 JPWO2019236631 A5 JP WO2019236631A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
och
nhc
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020567845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527051A (ja
JP2021527051A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035462 external-priority patent/WO2019236631A1/en
Publication of JP2021527051A publication Critical patent/JP2021527051A/ja
Publication of JPWO2019236631A5 publication Critical patent/JPWO2019236631A5/ja
Publication of JP2021527051A5 publication Critical patent/JP2021527051A5/ja
Pending legal-status Critical Current

Links

JP2020567845A 2018-06-05 2019-06-04 ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用 Pending JP2021527051A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862680891P 2018-06-05 2018-06-05
US62/680,891 2018-06-05
US201962831006P 2019-04-08 2019-04-08
US62/831,006 2019-04-08
PCT/US2019/035462 WO2019236631A1 (en) 2018-06-05 2019-06-04 Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses

Publications (3)

Publication Number Publication Date
JP2021527051A JP2021527051A (ja) 2021-10-11
JPWO2019236631A5 true JPWO2019236631A5 (https=) 2022-06-27
JP2021527051A5 JP2021527051A5 (https=) 2022-06-27

Family

ID=67185700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567845A Pending JP2021527051A (ja) 2018-06-05 2019-06-04 ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用

Country Status (5)

Country Link
US (1) US11046699B2 (https=)
EP (1) EP3802544A1 (https=)
JP (1) JP2021527051A (https=)
TW (1) TW202016112A (https=)
WO (1) WO2019236631A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499644B (zh) * 2020-04-24 2021-07-20 苏州大学 咪唑并[1,5-a]喹唑啉-5(4H)-酮类衍生物及其制备方法和用途
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
CN114516828A (zh) * 2020-11-19 2022-05-20 江苏威奇达药业有限公司 一种提高负氮杂提取率的提取工艺
US20250000859A1 (en) * 2021-08-25 2025-01-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
MX2024007328A (es) 2021-12-14 2024-09-30 Crossfire Oncology Holding B V Inhibidores macrociclicos de btk.
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors
CN116478145B (zh) * 2022-04-13 2024-02-02 杭州邦顺制药有限公司 Alk2激酶抑制剂
UY40234A (es) 2022-04-22 2023-11-15 Vertex Pharma Compuestos heteroarilo para el tratamiento del dolor
WO2024126617A1 (en) 2022-12-14 2024-06-20 Crossfire Oncology Holding B.V. Bifunctional compounds for degrading kinases via ubiquitin proteosome pathway
WO2024238570A1 (en) * 2023-05-15 2024-11-21 Aleksia Therapeutics, Inc. Cdk2 inhibitor pyrazolopyrimidine compounds
CN117756677B (zh) * 2023-12-21 2025-09-30 上海馨远医药科技有限公司 一种手性反式-n-boc-1-氨基环戊烷-3-甲酸的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CN1255392C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管生成抑制剂的秋水仙醇衍生物
ES2309206T3 (es) 2001-10-02 2008-12-16 Smithkline Beecham Corporation Compuestos quimicos.
EP2108019A2 (en) * 2007-01-30 2009-10-14 Biogen Idec MA, Inc. 1-h-pyrazolo[3,4b]pyrimidine derivatives and their use as modulators of mitotic kinases
US20130345268A1 (en) * 2009-02-13 2013-12-26 The Trustees Of Dartmouth College Methods and Compositions for the Treatment of RAS Associated Disorders
US8362023B2 (en) * 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
AU2014224976B2 (en) * 2013-03-05 2017-09-28 Merck Patent Gmbh 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
AU2014224975B2 (en) * 2013-03-05 2017-09-14 Merck Patent Gmbh Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer

Similar Documents

Publication Publication Date Title
JP2021527051A5 (https=)
JPWO2019236631A5 (https=)
JP2018519357A5 (https=)
JP2008505117A5 (https=)
JP2021514001A5 (https=)
RU2007109109A (ru) Дигидроптеридиноны, предназначенные для лечения раковых заболеваний
JP2024099041A5 (https=)
JP2006511490A5 (https=)
JP2020169171A5 (https=)
JP2021535104A5 (https=)
AR032569A1 (es) Ligandos del receptor de canabinoide
ES3046366T3 (en) Antiplatelet drugs and uses thereof
JP2015509927A5 (https=)
JP2005511699A5 (https=)
JP2006501292A5 (https=)
HRP20160046T1 (hr) Poboljšana citotoksiäśna sredstva koja sadrže nove majtanzinoide
JP2005505618A5 (https=)
JP2003506491A5 (https=)
AR040803A1 (es) Ligandos de receptores canabinoides, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o combinados, para la preparacion de medicamentos
RU2006128589A (ru) Стереоизомерные соединения и способы лечения желудочно-кишечных расстройств и расстройств центральной нервной системы
JP2005513125A5 (https=)
JP2005514420A5 (https=)
AR129722A1 (es) Compuestos inhibidores de axl
JP2015527355A5 (https=)
JP2009541225A5 (https=)